Eloralintide: Lilly's Amylin Drug With 20% Weight Loss

Twenty percent weight loss without a GLP-1 receptor in sight. That is the headline from eloralintide's Phase 2 trial, published in The Lancet in November 2025, and it forces a rethink of an assumption that has governed obesity pharmacology since 2021 — that pushing past the semaglutide ceiling requires stacking more incretin pathways. Eli Lilly's eloralintide (development code LY3841136) is a once-weekly selective amylin receptor agonist. It does not touch the GLP-1 receptor at all, yet at its top dose it matched the weight loss of tirzepatide's mid-range doses over 48 weeks. What makes the molecule genuinely novel is not the efficacy number but the design choice behind it: eloralintide was engineered to hit one specific amylin receptor subtype and largely avoid another, and that selectivity is the whole thesis.

Evidence: "Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment." — Billings LK, et al. The Lancet. 2025. DOI: 10.1016/S0140-6736(25)02155-5

What Makes Eloralintide a Selective Amylin Receptor Agonist

Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells after eating. It signals meal termination through receptor complexes in the area postrema and nucleus of the solitary tract — hindbrain regions that also govern nausea — then influences longer-term energy balance via hypothalamic projections. Native amylin survives only minutes in circulation, so every therapeutic amylin drug is an engineering exercise in making that signal last a week.

The complication is receptor architecture. Amylin receptors are not standalone proteins. They are heterodimers formed when the calcitonin receptor (CTR) pairs with one of three receptor activity-modifying proteins, producing AMY1R, AMY2R, and AMY3R. Because the calcitonin receptor is the shared backbone, a poorly designed amylin drug also activates CTR on its own — and CTR activation is linked to calcium lowering and bone turnover effects that have nothing to do with appetite.

Eloralintide was built to avoid exactly that. In cell-based assays it preferentially activated human AMY1R by 12-fold over the calcitonin receptor and 11-fold over AMY3R. Cagrilintide, the amylin component of CagriSema, is by contrast non-selective and engages CTR alongside the amylin receptors.

Evidence: "In vitro, eloralintide preferentially activated human AMY1R (12-fold > CTR, 11-fold > AMY3R)... Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05)." — Briere DA, et al. Molecular Metabolism. 2025. DOI: 10.1016/j.molmet.2025.102271

Conditioned taste avoidance is the standard rodent proxy for nausea — animals learn to avoid a flavor paired with a drug that makes them feel sick. Eloralintide produced significantly less of it than cagrilintide at comparable weight-loss effect. That preclinical signal is the origin of the tolerability claim that Lilly has built the program around, and as the clinical data below show, it survived translation to humans only partially.

The Phase 2 Results: 263 Adults, 48 Weeks, Six Dose Arms

The trial enrolled 263 adults across 46 US research centers. Participants were 18–75 years old with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity, and — importantly for interpretation — without type 2 diabetes. Baseline mean bodyweight was 109.1 kg and mean BMI was 39.1 kg/m², a heavier population than many competing trials. Randomization split participants across placebo, four fixed doses (1, 3, 6, and 9 mg once weekly), and two escalation schemes (6–9 mg and 3–9 mg).

Weight loss by dose at 48 weeks

Arm	n	Mean weight change	95% CI
Placebo	53	−0.4%	−2.2 to 1.4
Eloralintide 1 mg	28	−9%	−12.6 to −6.3
Eloralintide 3 mg	24	−12%	−14.9 to −9.8
Eloralintide 6 mg	28	−18%	−20.7 to −14.5
Eloralintide 9 mg	54	−20%	−22.7 to −17.5
Eloralintide 6–9 mg escalation	24	−20%	−22.7 to −17.0
Eloralintide 3–9 mg escalation	52	−16%	−18.6 to −14.1

Every arm met the primary endpoint. The dose-response is clean and monotonic across the fixed doses, which is exactly what a Phase 3 team wants to see before committing to a dose. Two details deserve attention. First, the placebo arm lost essentially nothing (−0.4%), meaning the entire effect is drug-attributable rather than inflated by lifestyle co-intervention — a contrast with trials where placebo groups drop 2–3%. Second, the 3–9 mg slow-escalation arm landed at −16%, four points below the 6–9 mg arm that reached the same final dose. Spending more weeks at low doses cost efficacy, a trade-off that matters when designing titration schedules.

The tolerability picture is more complicated than the headline

This is where the selective-receptor thesis meets messier reality. Nausea rates did not fall cleanly with dose:

Arm	Nausea	Fatigue
Placebo	14%	12%
1 mg	11%	0%
3 mg	13%	13%
6 mg	64%	29%
9 mg	33%	43%
6–9 mg	54%	46%
3–9 mg	25%	21%

The 6 mg arm reported 64% nausea while the higher 9 mg arm reported 33% — a non-monotonic pattern that almost certainly reflects small per-arm sample sizes (24–28 participants in several arms) rather than a real inverse dose relationship. What the table does show reliably: the two lowest doses were indistinguishable from placebo on nausea, the slow 3–9 mg escalation kept nausea to 25% while still delivering 16% weight loss, and fatigue rose with dose in a way that was consistent and dose-dependent. Fatigue at 43–46% in the top arms is a real finding and is not a side effect that dominates GLP-1 discussions.

The Phase 1 multiple-ascending-dose study, published separately, had suggested a gentler profile — 100 participants dosed for 12 weeks without escalation, with nausea in 8%, diarrhea in 10%, and vomiting in 4%.

Evidence: "Gastrointestinal adverse events, including diarrhoea (10% of participants), nausea (8%), and vomiting (4%), were infrequent in those receiving eloralintide... At Week 12 the least squares mean percent reduction in body weight across the dose groups ranged from 2.6% to 11.3%." — Bhattachar S, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70439

The honest reading is that eloralintide is better tolerated than a non-selective amylin agonist at equivalent weight loss, but the 48-week Phase 2 data do not support a claim of placebo-like tolerability at the doses that produce 20% weight loss. That distinction matters for patients choosing between mechanisms.

How Eloralintide Compares Across the Amylin Class

A 2026 network meta-analysis pooled six trials covering 4,642 participants and ranked amylin-based therapies against each other and against established GLP-1 drugs.

Evidence: "High dose subcutaneous amycretin produced the largest reduction in percent body weight (mean difference −23.95%; P score 1.00), followed by HiD eloralintide (−18.01%; P score 0.89) and HiD CagriSema (−17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (−11.45%) and liraglutide 3.0 mg (−6.4%)." — Kamrul-Hasan ABM, et al. Endocrinology, Diabetes & Metabolism. 2026. DOI: 10.1002/edm2.70247

That places eloralintide second in the class on efficacy, behind amycretin — though amycretin is a dual GLP-1/amylin molecule, not a pure amylin agonist, so it is not a like-for-like comparison. Against the pure amylin comparators, eloralintide's ~18–20% substantially exceeds petrelintide at 10.7% and cagrilintide monotherapy at roughly 10%. Notably, the same analysis found only high-dose CagriSema increased adverse-event-related discontinuation — eloralintide did not.

The strategic split within the class is now clear. Petrelintide is optimizing for tolerability and positioning as a gentle foundational backbone. Eloralintide is optimizing for magnitude, accepting more fatigue and nausea at top dose in exchange for weight loss that rivals dual agonists. Cagrilintide has largely abandoned monotherapy in favor of the CagriSema combination.

Caveats worth holding onto

The trial excluded people with type 2 diabetes, so nothing here predicts glycemic performance or weight loss in that population, where responses are consistently blunted. Per-arm sample sizes of 24–54 make individual adverse-event rates unstable. The study was funded by Eli Lilly and seven of ten authors are Lilly employees and stockholders — standard for industry trials, but relevant to how tolerability framing is presented. And critically, no body-composition data have been reported. The amylin class rests substantially on a lean-mass-sparing hypothesis; without DEXA data, whether eloralintide preserves muscle better than a GLP-1 remains an open question, not an established advantage.

What Happens Next

Lilly announced plans to begin Phase 3 studies of eloralintide as obesity monotherapy by the end of 2025 and is separately evaluating it as a complement to incretin therapy. The combination path is arguably the more consequential one. Lilly already owns tirzepatide and retatrutide; an amylin agonist that adds weight loss through an orthogonal pathway gives the company a combination it controls end-to-end — the same logic Novo Nordisk applied with CagriSema.

For patients, none of this is available yet. Phase 3 obesity programs typically run two to three years before submission, putting a realistic approval window in the late 2020s at the earliest. Nothing about the Phase 2 data changes what is prescribable today.

Key Takeaways

Eloralintide is a once-weekly selective AMY1R agonist that produces weight loss without engaging the GLP-1 receptor, using an entirely separate satiety pathway.
Phase 2 delivered up to 20% weight loss at 48 weeks (9 mg and 6–9 mg arms) against 0.4% for placebo, across 263 adults with a mean baseline BMI of 39 kg/m².
Receptor selectivity is the design thesis: 12-fold preference for AMY1R over the calcitonin receptor, which preclinically reduced nausea-proxy behavior versus cagrilintide.
Tolerability is good but not placebo-like at effective doses — nausea reached 33–64% and fatigue 43–46% in the top arms, though slow escalation cut nausea to 25% while still delivering 16% loss.
Body composition remains unmeasured, leaving the class's central muscle-sparing claim unproven in this trial.
Phase 3 monotherapy and incretin-combination programs are underway, with approval realistically years away.

Eloralintide's real contribution may be conceptual rather than clinical. It demonstrates that 20% weight loss is achievable through amylin biology alone, which means the pathway is not merely an additive partner for GLP-1 drugs but a viable primary mechanism. For patients who cannot tolerate incretin side effects, that is a meaningfully different future than one where every effective obesity drug runs through the same receptor.

References

Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631-2643. DOI: 10.1016/S0140-6736(25)02155-5
Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. DOI: 10.1016/j.molmet.2025.102271
Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026;28(4):2651-2660. DOI: 10.1111/dom.70439
Kamrul-Hasan ABM, Khalil I, Mahajan K, et al. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism. 2026;9(3):e70247. DOI: 10.1002/edm2.70247
Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026;196:171480. DOI: 10.1016/j.peptides.2026.171480
Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172. DOI: 10.1016/S0140-6736(21)01751-7

Last updated: 2026-07-18 Medical review: Dr. James Chen, MD, PhD, FACE